Login / Signup

Emerging drugs for the treatment of moderately to severely active ulcerative colitis: Review of phase II and III clinical trials.

Laura NeurathFerdinando D'AmicoSilvio Danese
Published in: Expert opinion on emerging drugs (2023)
We highlight the potential impact of these agents for the future therapeutic landscape in this disease with special emphasis on clinical impact, unmet needs, safety aspects and advanced combination therapy.
Keyphrases
  • combination therapy
  • phase ii
  • clinical trial
  • open label
  • ulcerative colitis
  • phase iii
  • double blind
  • placebo controlled
  • current status
  • single cell
  • study protocol
  • randomized controlled trial
  • replacement therapy